CG34M / CellenGene - LARVOL DELTA

Selengene, Mesothelin Targeting CAR-T Treatment New Patent Registration [Google translation] (Pharm News) - "Selengene...has set a new milestone in the field of cancer treatment by developing an innovative pancreatic cancer treatment. Selengene, which is leading the development of CAR-T treatment that allows T cells, an immune cell, to recognize cancer cells and attack only cancer cells, has discovered a new chimeric antigen receptor (CAR-T) targeting mesothelin and registered a patent....The newly developed and patented CG34M by Selengene is characterized by greatly improved binding affinity with mesothelin based on the existing CG34 CAR."

New molecule • Patent • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor